10x Genomics’s (NASDAQ:TXG) Q3 2026 sales top estimates but stock drops
10x Genomics reported Q3 2026 revenue of $150.7M, beating estimates by 1.8%, with EPS of -$0.15, a 42.8% beat. The company raised full-year revenue guidance to $630M. Operating margin improved to -10.7% from -21.6% YoY. Despite the beats, the stock dropped.
How this was made
The 30-second read
Why it matters
The earnings beat was insufficient to offset concerns over continued losses and modest guidance, leading to a share price decline.
Market read
Earnings surprise with a negative market reaction; traders may consider short positions or wait for further catalyst.
What to watch
Potential upcoming product launches or partnership announcements not disclosed yet may support longer‑term upside.
Background
10x Genomics reported Q3 2026 results with revenue of $150.7M, EPS of -$0.15, and raised full‑year revenue guidance to $630M.
Ticker impact
Q3 2026 earnings beat revenue and EPS estimates, but shares fell on guidance lift and margin outlook.
likely downside as investors price in modest guidance lift and still‑negative margin.
The surprise beat is outweighed by a modest revenue outlook and continued operating loss, prompting a sell‑off despite the beat.
Market effects
Biotech sequencing sector may see modest re‑rating as earnings highlight ongoing margin pressure.
US biotech indices could face slight pullback.
Limited to investors focused on genomics and precision medicine.
Counterpoint
The beat and guidance raise could be a buying opportunity if the market overreacts to the stock drop.
Key entities
- company10x Genomics
NASDAQ‑listed genomics technology firm.
